ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January
ScripVerona Pharma plc entered into agreements that give the company access to as much as $650m in new debt and other financing, bringing its new cash potential to more than $1bn after starting the year w
ScripA fortnight or so after Vertex Pharmaceuticals Incorporated ’s VX-548 achieved one of the vanishingly few breakthroughs by a non-opioid painkiller, a start-up has emerged to develop a similarly actin
Pink SheetCompanies that are developing local anesthetic products intended to have a long-acting effect should collect trial data on “clinically meaningful outcomes,” such as reduction in hospitalization, even